SIMCERE PHARMA announced that on December 27, 2024, it will spend 8.9501 million Hong Kong dollars to repurchase 1.321 million shares, with a repurchase price of 6.7-6.8547 Hong Kong dollars per share.
- Latest
- Detail
先声药业：12月27日斥资895.01万港元回购132.1万股
SIMCERE PHARMA: On December 27, spent 8.9501 million Hong Kong dollars to repurchase 1.321 million shares.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
13:25
In 2024, Global corporate borrowing surged to a record 8 trillion US dollars.
ABBV-0.66%
13:19
The micro-drama platform is still mining for profits from president dramas, enticing users to watch dramas with the temptation of earning cash through gold coins.
13:15
This year, the number of Leisure tourists in China is expected to exceed 0.5 billion.
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.